Novel treatments for castration-resistant prostate cancer. Review uri icon

Overview

abstract

  • The contemporary management of metastatic castration-resistant prostate cancer (mCRPC) is evolving dramatically. Understanding the biology of this disease, positive phase III studies and approvals for 4 novel agents in the US in 2010 and shortly in Europe have dramatically changed the therapeutic landscape.

publication date

  • September 1, 2011

Research

keywords

  • Carcinoma
  • Prostatic Neoplasms
  • Therapies, Investigational

Identity

Scopus Document Identifier

  • 80053273666

Digital Object Identifier (DOI)

  • 10.1016/S0959-8049(11)70165-4

PubMed ID

  • 21943975

Additional Document Info

volume

  • 47 Suppl 3